MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook
Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-yearRecord annual net sales performance surpasses $3B for first time, growing 14% as reported and 8% organicAdvanced global pipeline ahead of schedule with FDA clearance for MiniMed Flex™, CE Mark for Instinct, and global launch of MiniMed Go™ Smart MDINORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today reported financial results for its fourth quarter and full fiscal year ended April 24, 2026.
"MiniMed delivered a strong finish to our fiscal year, driven by strength in international markets
